Compare Bristol-Myers Squibb Co (BMY) vs Matson Inc (MATX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Matson Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.5 (market cap $116.30B), while Matson Inc trades at $210.22 (market cap $6.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 18.2× Matson Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | MATX | |
|---|---|---|
Market Cap | $116.30B | $6.38B |
Sector | Health | Technology |
52-Week High | $62.37 | $210.95 |
52-Week Low | $42.60 | $88.05 |
Enterprise Value | $152.24B | $6.98B |
Dividend Yield | 4.42% | 0.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Matson (MATX) trades at $205.15, up 0.19% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong profitability with a 12.92% net income margin and consistent earnings beats in recent quarters. Recent developments include a dividend increase to $0.38 per share and progress on its LNG-powered vessel construction program, highlighting operational strength and shareholder returns.
The outlook for MATX is positive, supported by niche Pacific shipping routes and resilient earnings. Key opportunities include growth in expedited China service and share repurchases. Risks involve exposure to trade volatility and potential margin pressure from higher costs. Analyst consensus is bullish with 64% buy ratings, but investors should monitor global trade flows and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →
